Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
Last trade$2.80
Day change+$0.31 (+12.45%)
Day range$2.20 – $2.87
Volume261,802
Market cap$13M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$12.53M
Price / earnings
—
Price / book
0.61×
Price / sales
0.17×
EV / sales
0.36×
EV / EBITDA
-1.6×
Profitability
Earnings per share
-$4.85
Return on assets
-39.68%
Return on equity
-117.98%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.78×
Current ratio
1.05×
Quick ratio
0.92×
Cash ratio
0.05×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.93M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for COSM, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$18.99M
$17.93M
$19.7M
$17.11M
$14.75M
$13.71M
$14.22M
$12.41M
Cost of revenue
$17.47M
$16.55M
$17.62M
$14.51M
$13.58M
$11.66M
$13.22M
$11.2M
Gross profit
$1.51M
$1.38M
$2.08M
$2.6M
$1.16M
$2.05M
$1M
$1.21M
Selling, general and administrative
$4.02M
$3.22M
$12.6M
$4.03M
$3.38M
$2.55M
$8.83M
$3.14M
Research and development
$68.55K
$0
$410.76K
$18.34K
$74.64K
$15.63K
$533.29K
$0
Total operating expenses
$4.44M
$3.57M
$13.49M
$4.42M
$3.81M
$2.88M
$9.97M
$3.45M
Operating income
-$2.93M
-$2.18M
-$11.41M
-$1.82M
-$2.65M
-$833.15K
-$8.97M
-$2.24M
Interest expense
-$1M
-$813.58K
-$1.01M
-$870.6K
-$551.92K
-$187.11K
-$319.77K
-$181.43K
Income before taxes
-$6.09M
-$2.81M
-$10.15M
-$5.35M
-$2.83M
-$818.1K
-$9.54M
-$2.18M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.09M
-$2.81M
-$10.15M
-$5.35M
-$2.83M
-$818.1K
-$9.54M
-$2.18M
Net income attributable to common shareholders
-$6.09M
-$2.81M
-$10.15M
-$5.35M
-$2.83M
-$818.1K
-$9.54M
-$8.38M
EBITDA
-$2.58M
-$1.84M
-$10.92M
-$1.44M
-$2.29M
-$517.31K
-$8.34M
-$1.94M
Basic earnings per share
-$0.10
-$0.06
-$0.28
-$0.17
-$0.10
-$0.03
-$0.41
-$0.45
Diluted earnings per share
-$0.10
-$0.06
-$0.28
-$0.17
-$0.10
-$0.03
-$0.41
-$0.45
Recent news
Company coverage with links to the original publishers.
Cosmos Health Inc. (NASDAQ: COSM) announced a non-binding letter of intent to acquire 100% of Doc Pharma S.A., a European GMP-licensed pharmaceutical manufacturer. The acquisition is expected to be immediately accretive, expanding Cosmos Health's asset base by approximately $24 million, adding $6.7 million in average annual revenue and $3.2 million in gross profit. The deal aims to deepen vertical integration, improve margins, expand production capacity, and strengthen the company's R&D capabilities. The transaction is subject to independent director review, fairness opinion, and shareholder approval.
Cosmos Health Inc. purchased an additional $500,000 in Ethereum, bringing its total investment to $1.5 million under its $300 million digital assets facility, aiming to diversify its balance sheet and explore blockchain technology in healthcare.
Cosmos Health's subsidiary SkyPharm signed an exclusive distribution agreement with Diyar United to market Sky Premium Life nutraceuticals in Kuwait, securing an initial purchase order of over 65,000 units in a market projected to reach $1.68 billion by 2030.
Cosmos Health enters the U.S. nutraceuticals market with its Sky Premium Life brand, launching NOOR Collagen and expecting 75% gross margins and over $12M in annualized revenue from the product.
Cosmos Health signed a distribution agreement with Scientific Pharmacy in Oman for Sky Premium Life food supplements, securing an initial purchase order of 42,000 units in the rapidly growing $7 billion GCC nutraceuticals market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.